Literature DB >> 15774430

Depression in multiple sclerosis: a review.

R J Siegert1, D A Abernethy.   

Abstract

Several studies have reported high rates of depression in multiple sclerosis (MS) with a lifetime prevalence of approximately 50% and an annual prevalence of 20% not uncommon. Concern about the potential of new drug treatments to exacerbate or precipitate depression in MS has led to increased interest in the relation between MS and depression. This review on MS and depression identifies the following key issues: How common is depression in people with MS? Is depression in MS associated with lesions in specific regions of the central nervous system? Is there an increased risk of suicide in MS? Is there a higher than expected incidence of anxiety disorders in MS? Are fatigue and depressed mood related in MS? Is there a relation between depression and cognitive impairment in MS? Which psychosocial variables affect the development of depression in MS? Does treatment with interferon increase the risk of depression? How effective are treatments for MS patients with depression? Each of these issues is briefly reviewed with critical commentary, and some priorities for future research are suggested.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774430      PMCID: PMC1739575          DOI: 10.1136/jnnp.2004.054635

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  77 in total

1.  Suicide and multiple sclerosis: an epidemiological investigation.

Authors:  E N Stenager; E Stenager; N Koch-Henriksen; H Brønnum-Hansen; K Hyllested; K Jensen; U Bille-Brahe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-07       Impact factor: 10.154

2.  Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.

Authors:  Lydia Chwastiak; Dawn M Ehde; Laura E Gibbons; Mark Sullivan; James D Bowen; George H Kraft
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

3.  Assessing depressive symptoms in multiple sclerosis: is it necessary to omit items from the original Beck Depression Inventory?

Authors:  J E Aikens; M A Reinecke; N H Pliskin; J S Fischer; J S Wiebe; L M McCracken; J L Taylor
Journal:  J Behav Med       Date:  1999-04

4.  Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis.

Authors:  J Pujol; J Bello; J Deus; J L Martí-Vilalta; A Capdevila
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

5.  The role of helplessness as mediator between neurological disability, emotional instability, experienced fatigue and depression in patients with multiple sclerosis.

Authors:  S P van der Werf; A Evers; P J H Jongen; G Bleijenberg
Journal:  Mult Scler       Date:  2003-02       Impact factor: 6.312

6.  An examination of suicidal intent in patients with multiple sclerosis.

Authors:  Anthony Feinstein
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

7.  Comparative assessment of Yale Single Question and Beck Depression Inventory Scale in screening for depression in multiple sclerosis.

Authors:  Jagannadha R Avasarala; Anne H Cross; Kathryn Trinkaus
Journal:  Mult Scler       Date:  2003-06       Impact factor: 6.312

8.  Mood disorder and multiple sclerosis.

Authors:  R T Joffe; G P Lippert; T A Gray; G Sawa; Z Horvath
Journal:  Arch Neurol       Date:  1987-04

9.  Psychosocial correlates of fatigue in multiple sclerosis.

Authors:  C E Schwartz; L Coulthard-Morris; Q Zeng
Journal:  Arch Phys Med Rehabil       Date:  1996-02       Impact factor: 3.966

10.  Depression in multiple sclerosis.

Authors:  S L Minden; J Orav; P Reich
Journal:  Gen Hosp Psychiatry       Date:  1987-11       Impact factor: 3.238

View more
  151 in total

1.  Treatment of mood disorders in multiple sclerosis.

Authors:  Luis Pintor Pérez; Roberto Sánchez González; Eva Baillés Lázaro
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

Review 2.  Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions.

Authors:  Kristen Farrell; Michael H Antoni
Journal:  Fertil Steril       Date:  2010-05-14       Impact factor: 7.329

3.  Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms.

Authors:  Stefan M Gold; Kyle C Kern; Mary-Frances O'Connor; Michael J Montag; Aileen Kim; Ye S Yoo; Barbara S Giesser; Nancy L Sicotte
Journal:  Biol Psychiatry       Date:  2010-06-19       Impact factor: 13.382

4.  Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.

Authors:  Kerri A Schoedel; Laura E Pope; Edward M Sellers
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

5.  Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

Authors:  Ida S Haussleiter; Martin Brüne; Georg Juckel
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

Review 6.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

7.  Prevalence and predictors of depression in Iranian patients with multiple sclerosis: a population-based study.

Authors:  Seyed Mohammad Seyed Saadat; Mozaffar Hosseininezhad; Babak Bakhshayesh; Seyedeh Nastaran Seyed Saadat; Seyedeh Parand Nabizadeh
Journal:  Neurol Sci       Date:  2013-12-10       Impact factor: 3.307

8.  Self-efficacy as a predictor of self-reported physical, cognitive, and social functioning in multiple sclerosis.

Authors:  Margaret M Schmitt; Yael Goverover; John Deluca; Nancy Chiaravalloti
Journal:  Rehabil Psychol       Date:  2013-12-09

Review 9.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

10.  Depression and wish to die in a multicenter cohort of ALS patients.

Authors:  Judith G Rabkin; Raymond Goetz; Pam Factor-Litvak; Jonathan Hupf; Martin McElhiney; Jessica Singleton; Hiroshi Mitsumoto
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-12-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.